GENE ONLINE|News &
Opinion
Blog

2020-08-19| R&DSpecialTechnology

A Novel Tool to Augment Checkpoint Inhibitor Cancer Therapy

by Ruchi Jhonsa
Share To
Washington University School of Medicine researchers uncover the mechanism by which tumor-infiltrating myeloid cells create suppressive microenvironments. The findings provide a novel approach for augmenting the effects of checkpoint blockade therapies. The suppressive tumor environment affects T cell responses by engaging immune checkpoint proteins such as PD-1.

GO Prime with only $1.49 now

LATEST
Oncology’s New Drugs on the Horizon (II): Radiotherapy, Radioligands & Other Therapeutic Agents
2024-04-12
Oncology’s New Drugs on the Horizon (I): Cancer Immunotherapy and Targeted Therapy
2024-04-12
Vertex Pharmaceuticals Makes $4.9 Billion Bet on Kidney Disease Treatment through Alpine Immune Acquisition
2024-04-11
Bayer Signs New Partnership with Google Cloud, Joining Hands for AI Solutions for Radiologists
2024-04-10
Pharmacogenomics (PGx) Shaping the Dynamic APAC Regions
2024-04-10
Connecting Biotech Ecosystems: Success of Los Angeles Event Sets Stage for APAC-US Collaboration
2024-04-10
Innovating Prostate Cancer Care: SYNC-T, Proteogenomics, and Culturally Tailored Education at AACR 2024
2024-04-10
EVENT
Scroll to Top